|
nasdaq:mnkd
|
16777
|
Apr 21st, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 20th, 2024 11:47PM
|
Apr 20th, 2024 11:47PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 20th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
539.00
|
Open
|
|
Apr 19th, 2024 11:45PM
|
Apr 20th, 2024 05:19PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 19th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 18th, 2024 11:52PM
|
Apr 18th, 2024 11:52PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 18th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 18th, 2024 12:00AM
|
Apr 18th, 2024 06:40PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 17th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 16th, 2024 11:42PM
|
Apr 17th, 2024 03:05PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 16th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 15th, 2024 11:38PM
|
Apr 16th, 2024 11:21AM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 15th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 14th, 2024 11:34PM
|
Apr 15th, 2024 05:03PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 14th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
539.00
|
Open
|
|
Apr 13th, 2024 11:22PM
|
Apr 13th, 2024 11:22PM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 13th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
539.00
|
Open
|
|
Apr 12th, 2024 11:14PM
|
Apr 13th, 2024 11:48AM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|
|
nasdaq:mnkd
|
16777
|
Apr 12th, 2024 12:00AM
|
MannKind Corporation
|
11K
|
540.00
|
Open
|
|
Apr 11th, 2024 11:19PM
|
Apr 12th, 2024 08:43AM
|
MannKind Corporation (Nasdaq: MNKD) focuses on the development and commercialization of innovative therapeutic products and devices to address serious unmet medical needs for those living with endocrine and orphan lung diseases.
We are committed to using our formulation capabilities and device engineering prowess to lessen the burden of diseases such as diabetes, pulmonary arterial hypertension (PAH) and nontuberculous mycobacterial (NTM) lung disease. Our signature technologies – dry-powder formulations and inhalation devices – offer rapid and convenient delivery of medicines to the deep lung where they can exert an effect locally or enter the systemic circulation.
With a passionate team of Mannitarians collaborating nationwide, we are on a mission to give people control of their health and the freedom to live life.
Please visit mannkindcorp.com to learn more
|
Open
|
|
Open
|
1 Casper Street
|
Danbury
|
CT
|
US
|
06810-6903
|
|
MannKind
|
Health Care
|
Pharmaceuticals & Biotechnology
|